Chris Calhoun Sees Breasts As Future of Regenerative Medicine

RoseTracker| In what’s meant to be a serious Wired magazine article called All Natural: Why Breasts Are the Key to the Future of Regenerative Medicine, I want to share with readers the inside-Wired web name for this photo. It’s called ‘ff_future ofboobs_f.

Ah yes, the boys will be boys, even when the subject is breast rejuvenation and what Chris Calhoun, the 44-year-old CEO of San Diego-based biotech company Cytori Therapeutics, calls a new discovery in tissue engineering “a process that could well be one of the most momentous medical advances of the 21st century: the use of stem cells—specifically stem-cell-enriched adipose (fat) tissue—to enhance, heal, and rebuild injured or damaged organs.”

Obviously, the women’s beauty breast enhancement business comes to mind. Perking-up was a $964 business to plastic surgeons in 2009, making it the number one procedure.

Calhoun argues procedures represent a critical offering to the one in eight women in America who get breast cancer in her lifetime. As breast cancer recovery rates bloom positively, women are left with significant decisions about breast reconstruction.

Today 90 percent of women diagnosed with breast cancer live five years or longer.

Chris Calhoun is dreaming about far more than breasts. His plan is to introduce regenerative stem cell medicine to the mass market, without using human embryos.

Instead, based on almost a decade of trials that Cytori and its academic partners have performed on cell cultures, lab rodents, and now humans, they believe their engineered flab cells can treat more organs than you find in a French butcher shop. Chronic heart disease? Check: In human studies released in May, the cells improved patients’ aerobic capacity and shrank the size of the infarct (tissue killed by lack of blood). Heart attack? Check: A human clinical trial, also reported in May, found that the cells increased both the blood supply to damaged heart muscle and the volume of blood that the heart pumped. Kidney injury as a result of cancer therapy? Check: In recent rat studies, the cells improved kidney function. Incontinence after prostatectomy? Check: Another recent study reported that, by 12 weeks after injection, the cells had decreased the amount of urine male volunteers were leaking by 89 percent. If Calhoun and his scientists succeed, they won’t just create more cleavage. They’ll make practical a whole new field, one that medical visionaries have dreamed of for decades: regenerative medicine. via Wired